Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors

NCT06182579 is registered in ClinicalTrials.gov with Coordination Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06182579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06182579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors
Lead sponsor
Coordination Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 22, 2024
Completion date
June 16, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, intratumoral injection